Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms. This study aimed to evaluate the in vitro activity of ceftolozane–tazobactam against clinical bacterial isolates at the University Hos...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | New Microbes and New Infections |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297521000366 |
id |
doaj-4251c23d5299490daff37280c805cc77 |
---|---|
record_format |
Article |
spelling |
doaj-4251c23d5299490daff37280c805cc772021-06-03T04:56:22ZengElsevierNew Microbes and New Infections2052-29752021-05-0141100872Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 studyJ. Belkhair0S. Nachat1S. Rouhi2H. Ouassif3S. Abbassi4N. Soraa5Corresponding author: J. Belkhair, Laboratory of Microbiology, Arrazi Hospital, University hospital center of Marrakech, Morocco.; Laboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoLaboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoLaboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoLaboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoLaboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoLaboratory of Microbiology, Arrazi Hospital, University Hospital Center of Mohamed VI, Faculty of Medecine & Pharmacy, Cadi Ayyad University, Marrakech, MoroccoCeftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms. This study aimed to evaluate the in vitro activity of ceftolozane–tazobactam against clinical bacterial isolates at the University Hospital of Marrakech. This is a descriptive and analytical prospective study. A total of 143 Enterobacterales and 48 Pseudomonas aeruginosa isolates were collected from January 2018 to December 2018 from patients with respiratory, urinary and intra-abdominal infections. The identification was made by Phoenix automated system (BioMérieux). MIC50/90 were tested by broth microdilution for ceftolozane-tazobactam, and other drugs using dried panels. Antimicrobial susceptibility results were interpreted according to CLSI guidelines. Ceftolozane-tazobactam inhibited 98% of Escherichia coli (MIC50/90; 0.25/0.5 μg/mL). The susceptibility rate of Klebsiella pneumoniae to ceftolozane-tazobactam was 68.8% (MIC50/90, 0.5/>32 μg/mL); other Enterobacterales have shown susceptibility rates of 80.4% (MIC50/90; 0.5/8 μg/mL). In carbapenemase-producing K. pneumoniae, the blaOXA-48 mutation was found in two isolates. Susceptibility of P. aeruginosa to ceftolozane-tazobactam was 91.7% (MIC50/90, 0.5/>32 μg/mL). In non-carbapenemase-producing P. aeruginosa, AmpC mutations were found in all isolates. Ceftolozane-tazobactam was satisfactorily active against a wide range of tested isolates and offers clinicians a potential therapeutic option even against resistant strains in patients with intra-abdominal infections, urinary tract infections and nosocomial pneumonia.http://www.sciencedirect.com/science/article/pii/S2052297521000366Antimicrobial susceptibilityceftolozane-tazobactamEnterobacteralesminimum inhibitory concentrationsPseudomonas aeruginosa |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
J. Belkhair S. Nachat S. Rouhi H. Ouassif S. Abbassi N. Soraa |
spellingShingle |
J. Belkhair S. Nachat S. Rouhi H. Ouassif S. Abbassi N. Soraa Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study New Microbes and New Infections Antimicrobial susceptibility ceftolozane-tazobactam Enterobacterales minimum inhibitory concentrations Pseudomonas aeruginosa |
author_facet |
J. Belkhair S. Nachat S. Rouhi H. Ouassif S. Abbassi N. Soraa |
author_sort |
J. Belkhair |
title |
Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study |
title_short |
Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study |
title_full |
Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study |
title_fullStr |
Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study |
title_full_unstemmed |
Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study |
title_sort |
evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against enterobacterales and pseudomonas aeruginosa—the em200 study |
publisher |
Elsevier |
series |
New Microbes and New Infections |
issn |
2052-2975 |
publishDate |
2021-05-01 |
description |
Ceftolozane-tazobactam is a cephalosporin/β-lactamase inhibitor combination developed for use against some β-lactam- and multidrug-resistant Gram-negative organisms. This study aimed to evaluate the in vitro activity of ceftolozane–tazobactam against clinical bacterial isolates at the University Hospital of Marrakech. This is a descriptive and analytical prospective study. A total of 143 Enterobacterales and 48 Pseudomonas aeruginosa isolates were collected from January 2018 to December 2018 from patients with respiratory, urinary and intra-abdominal infections. The identification was made by Phoenix automated system (BioMérieux). MIC50/90 were tested by broth microdilution for ceftolozane-tazobactam, and other drugs using dried panels. Antimicrobial susceptibility results were interpreted according to CLSI guidelines. Ceftolozane-tazobactam inhibited 98% of Escherichia coli (MIC50/90; 0.25/0.5 μg/mL). The susceptibility rate of Klebsiella pneumoniae to ceftolozane-tazobactam was 68.8% (MIC50/90, 0.5/>32 μg/mL); other Enterobacterales have shown susceptibility rates of 80.4% (MIC50/90; 0.5/8 μg/mL). In carbapenemase-producing K. pneumoniae, the blaOXA-48 mutation was found in two isolates. Susceptibility of P. aeruginosa to ceftolozane-tazobactam was 91.7% (MIC50/90, 0.5/>32 μg/mL). In non-carbapenemase-producing P. aeruginosa, AmpC mutations were found in all isolates. Ceftolozane-tazobactam was satisfactorily active against a wide range of tested isolates and offers clinicians a potential therapeutic option even against resistant strains in patients with intra-abdominal infections, urinary tract infections and nosocomial pneumonia. |
topic |
Antimicrobial susceptibility ceftolozane-tazobactam Enterobacterales minimum inhibitory concentrations Pseudomonas aeruginosa |
url |
http://www.sciencedirect.com/science/article/pii/S2052297521000366 |
work_keys_str_mv |
AT jbelkhair evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study AT snachat evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study AT srouhi evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study AT houassif evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study AT sabbassi evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study AT nsoraa evaluationofinvitroactivityofceftolozanetazobactamincombinationwithotherclassesofantibacterialagentsagainstenterobacteralesandpseudomonasaeruginosatheem200study |
_version_ |
1721399690868555776 |